<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Gong, W.</style></author><author><style face="normal" font="default" size="100%">Panoutsopoulou, K.</style></author><author><style face="normal" font="default" size="100%">Singer-Cornelius, T.</style></author><author><style face="normal" font="default" size="100%">Augustin, K.</style></author><author><style face="normal" font="default" size="100%">Bronger, H.</style></author><author><style face="normal" font="default" size="100%">Kiechle, M.</style></author><author><style face="normal" font="default" size="100%">Dorn, J.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author><author><style face="normal" font="default" size="100%">Magdolen, V.</style></author><author><style face="normal" font="default" size="100%">Dreyer, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Cancer Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomarker</style></keyword><keyword><style  face="normal" font="default" size="100%">chemoresistance</style></keyword><keyword><style  face="normal" font="default" size="100%">miR-206</style></keyword><keyword><style  face="normal" font="default" size="100%">miR-214</style></keyword><keyword><style  face="normal" font="default" size="100%">miR-27a</style></keyword><keyword><style  face="normal" font="default" size="100%">miRNA</style></keyword><keyword><style  face="normal" font="default" size="100%">triple-negative breast cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year></dates><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">2471-2487</style></pages><isbn><style face="normal" font="default" size="100%">2156-6976 (Print)2156-6976 (Electronic)2156-6976 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, associated with early metastasis and recurrence as well as poor patient outcome. TNBC does not or weakly respond to hormonal or HER2-targeted therapies. Therefore, there is a strong need to identify other potential molecular targets for TNBC therapy. Micro-RNAs play important roles in the post-transcriptional regulation of gene expression. Thus, micro-RNAs, displaying an association between elevated expression and poor patient prognosis, may represent candidates for such novel tumor targets. In the present study, we evaluated the prognostic impact of miR-27a, miR-206, and miR-214 in TNBC via qPCR in tumor tissue (n=146). In univariate Cox regression analysis, elevated expression of all three analyzed micro-RNAs was significantly associated with shortened disease-free survival (hazard ratio [HR] for miR-27a: 1.85, P=0.038; miR-206: 1.83, P=0.041; miR-214: 2.06, P=0.012). In multivariable analysis, the micro-RNAs remained independent biomarkers for disease-free survival (HR for miR-27a: 1.99, P=0.033; miR-206: 2.14, P=0.018; miR-214: 2.01, P=0.026). Furthermore, our results suggest that elevated levels of these micro-RNAs are linked to enhanced resistance to chemotherapy. Based on the association of high expression levels with shortened patient survival and increased chemoresistance, miR-27a, miR-206, and miR-214 may represent novel molecular targets for TNBC.</style></abstract><accession-num><style face="normal" font="default" size="100%">37424802</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, YueyangGong, WeiweiPanoutsopoulou, KonstantinaSinger-Cornelius, ThirzaAugustin, KatharinaBronger, HolgerKiechle, MarionDorn, JuliaScorilas, AndreasAvgeris, MargaritisMagdolen, ViktorDreyer, Tobiaseng2023/07/10 06:42Am J Cancer Res. 2023 Jun 15;13(6):2471-2487. eCollection 2023.</style></notes><custom2><style face="normal" font="default" size="100%">PMC10326573</style></custom2><auth-address><style face="normal" font="default" size="100%">Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich Munich, Germany.Department of Gynecology, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences Guangzhou, Guangdong, People's Republic of China.Department of Hematology-Oncology, Guangzhou Women and Children's Medical Center Guangzhou, Guangdong, People's Republic of China.Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens Athens 15771, Greece.German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Center (DKFZ) Heidelberg, Germany.Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, &quot;P. &amp; A. Kyriakou&quot; Children's Hospital Athens 11527, Greece.</style></auth-address></record></records></xml>